Comparison
22q Partial Monosomy C0265489 vs 15q11q13 Microduplication Syndrome C2675336
Clinical comparison between 22q Partial Monosomy and 15q11q13 Microduplication Syndrome for differential diagnosis and treatment planning.
22q Partial Monosomy C0265489
A genetic disorder from missing material on chromosome 22, often called DiGeorge syndrome. It can affect the heart, immune system, and development. Requires lifelong specialized medical care.
15q11q13 Microduplication Syndrome C2675336
A genetic disorder involving duplication of material from the chromosome 15 region linked to Prader-Willi and Angelman syndromes. Features may include developmental delays, learning difficulties, and sometimes autism spectrum traits. Supportive therapies help manage symptoms.
6 comparison axes
Onset
22q Partial Monosomy C0265489
0-null
15q11q13 Microduplication Syndrome C2675336
0-3
Onset patterns differ
Severity
22q Partial Monosomy C0265489
severe
15q11q13 Microduplication Syndrome C2675336
moderate
Different severity levels
Chronic
22q Partial Monosomy C0265489
Chronic
15q11q13 Microduplication Syndrome C2675336
Chronic
Differing course
Communicable
22q Partial Monosomy C0265489
No
15q11q13 Microduplication Syndrome C2675336
No
Different transmission
Body System
22q Partial Monosomy C0265489
congenital
15q11q13 Microduplication Syndrome C2675336
congenital
Same/different system
Category
22q Partial Monosomy C0265489
rare-disease
15q11q13 Microduplication Syndrome C2675336
genetic
Different category
Bottom line
22q-partial-monosomy-C0265489 and 15q11q13-microduplication-syndrome-C2675336 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 22q Partial Monosomy C0265489 | 15q11q13 Microduplication Syndrome C2675336 | Discriminating power |
|---|---|---|---|
| Genetic change | Missing chromosome 22 material; often discussed within the 22q11.2 deletion spectrum. | Extra material from 15q11q13, a region also linked to Prader-Willi and Angelman syndromes. | High |
| Multisystem congenital features | Heart and immune involvement may occur, but neither feature is universal or diagnostic alone. | Cardiac or immune disease is not established by the supplied description. | Moderate |
| Neurodevelopment | Developmental effects may occur alongside other congenital findings. | Developmental delay, learning difficulty, and sometimes autism-spectrum traits are described. | Moderate |
When to favor each condition
Choose 22q Partial Monosomy C0265489 when
A confirmed chromosome 22 copy-number loss
The laboratory finding directly matches the left condition, pending clinical correlation.
High
Congenital heart or immune concerns with suspected 22q deletion
These features fit the supplied left description better than the right.
Moderate
Severe multisystem congenital presentation
The source classifies the left condition as severe, but severity alone cannot diagnose it.
Low
Choose 15q11q13 Microduplication Syndrome C2675336 when
A confirmed 15q11q13 duplication
The specific copy-number gain identifies the right condition, with phenotype interpreted clinically.
High
Developmental delay, learning difficulty, or autism-spectrum traits
These are the principal features supplied for the right condition.
Moderate
Moderate neurodevelopmental presentation without established cardiac-immune disease
This pattern is more consistent with the supplied right description, but testing is still required.
Low
How key tests differ
| Test | 22q Partial Monosomy C0265489 | 15q11q13 Microduplication Syndrome C2675336 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | Copy-number loss involving chromosome 22. | Copy-number gain at 15q11q13. | The result is a genetic finding; size, genes, inheritance, and phenotype need clinician interpretation. |
| Targeted FISH or MLPA | May detect a 22q deletion only when the assay covers the region. | A 22q-targeted assay would not be expected to identify a 15q duplication. | A negative targeted test does not exclude another copy-number variant. |
| Clinical system evaluation | Cardiac and immune assessments are often relevant. | Developmental and behavioral assessments are often central. | Abnormal results support evaluation but are not themselves diagnoses. |
Prognosis comparison
22q Partial Monosomy C0265489
- Outcome
- Often a lifelong condition with variable multisystem needs; exact outcomes are not established here.
- Factors
- Confirmed deletion, cardiac or immune involvement, development, and access to specialized care.
15q11q13 Microduplication Syndrome C2675336
- Outcome
- Often chronic but variable developmental needs; exact outcomes are not established here.
- Factors
- Duplication details, learning or autism-related needs, comorbidities, and therapy access.
Time frame: Lifelong, with needs changing across development.
Supplied data support different severity patterns but do not establish mortality or individual prognosis.
Complications comparison
| Complication | Presentation |
|---|---|
| Cardiac involvement | Congenital heart findings may occur. Not established from the supplied source. Any suspected cardiac abnormality requires individual clinical assessment. |
| Immune vulnerability | Immune-system effects and infection susceptibility may occur. Not described in the supplied source. An immune abnormality is a finding requiring specialist interpretation, not a diagnosis by itself. |
| Learning and behavior | Developmental difficulties may contribute to long-term needs. Learning difficulty and sometimes autism-spectrum traits are described. Support needs vary; no single complication is inevitable. |
Patient education highlights
- HighGenetic confirmation
Diagnosis depends on the specific chromosomal result and clinical interpretation, not symptoms alone.
- HighTransmission
Neither condition is communicable. Inheritance and recurrence require genetic counseling.
- MediumCare planning
Left may need lifelong multisystem care; right is generally managed with supportive developmental therapies.